key: cord-0828612-28dzd6wj authors: Mazzetti, Samanta; Barichella, Michela; Giampietro, Federica; Giana, Angelica; Calogero, Alessandra M; Amadeo, Alida; Palazzi, Nicola; Comincini, Alessandro; Giaccone, Giorgio; Bramerio, Manuela; Caronni, Serena; Cereda, Viviana; Cereda, Emanuele; Cappelletti, Graziella; Rolando, Chiara; Pezzoli, Gianni title: Astrocytes expressing Vitamin D‐activating enzyme identify Parkinson’s disease date: 2022-02-15 journal: CNS Neurosci Ther DOI: 10.1111/cns.13801 sha: d789f3869eaf6b87c5e85dbee6b142bf993798a8 doc_id: 828612 cord_uid: 28dzd6wj INTRODUCTION: Astrocytes are involved in Parkinson's disease (PD) where they could contribute to α‐Synuclein pathology but also to neuroprotection via α‐Synuclein clearance. The molecular signature underlying their dual role is still elusive. Given that vitamin D has been recently suggested to be protective in neurodegeneration, the aim of our study was to investigate astrocyte and neuron vitamin D pathway alterations and their correlation with α‐Synuclein aggregates (ie, oligomers and fibrils) in human brain obtained from PD patients. METHODS: The expression of vitamin D pathway components CYP27B1, CYP24A1, and VDR was examined in brains obtained from PD patients (Braak stage 6; n = 9) and control subjects (n = 4). We also exploited proximity ligation assay to identified toxic α‐Synuclein oligomers in human astrocytes. RESULTS: We found that vitamin D‐activating enzyme CYP27B1 identified a subpopulation of astrocytes exclusively in PD patients. CYP27B1 positive astrocytes could display neuroprotective features as they sequester α‐Synuclein oligomers and are associated with Lewy body negative neurons. CONCLUSION: The presence of CYP27B1 astrocytes distinguishes PD patients and suggests their contribution to protect neurons and to ameliorate neuropathological traits. Astrocytes are key players in Parkinson's disease (PD). 1-3 α-Synuclein misfolding and aggregation in neurons is the key hallmark of PD that associates with neuropathological deterioration. 4 Astrocytes positively respond in PD as they can internalize and degrade α-Synuclein aggregates thus protecting neurons. 1, 5 . On the contrary, the acquisition of inflammatory and altered metabolic properties in astrocytes results in detrimental effects and can potentially exacerbate the damage. 6, 7 Therefore, identifying glial specific mechanisms that promote the acquisition of protective phenotype can be beneficial for treating PD. The activation of vitamin D pathway has been linked to neuroprotection. 8 Vitamin D 3 (25-hydroxyvitamin D [25(OH)D]) is present in the serum, and it needs to be activated by 25-hydroxyvitamin D1α-hydroxylase (CYP27B1) in order to exert its biological function. 9 CYP27B1 and 1,25-dihydroxyvitamin D receptor (VDR) are expressed by neurons and glial cells in post-mortem human brain indicating that the vitamin D can be locally activated. 10, 11 PD patients are usually characterized by lower 25(OH)D levels than controls 12 and reduced serum 25(OH)D and polymorphisms in VDR have been associated with increased susceptibility to PD. 13 Furthermore, lower serum concentrations have been observed in patients with the more severe symptoms including impaired cognitive functions. [14] [15] [16] [17] Interestingly, vitamin D supplementation can slow Hoehn-Yahr stage deterioration, particularly in patients carrying vitamin D receptor polymorphisms. 13 In addition, vitamin D supplementation in PD patients has been recently suggested to play a protective role also in COVID-19 symptoms. 18 Despite the important role of vitamin D in PD, it is unknown whether the expression of the key signaling components is altered during the disease. 14 We therefore aimed to analyze the distribution and localization of vitamin D-activating and degrading enzymes CYP27B1 and CYP24A1 (25-Hydroxyvitamin D-24hydroxylase) and VDR in post-mortem human brain (Braak stage 6) of PD patients. We observed that CYP27B1 was specifically increased in an astrocyte subpopulation of PD patients, exclusively in brain regions involved in the pathology. Furthermore, we investigated the involvement of CYP27B1 positive astrocytes in α-Synuclein pathology and we correlated their expression with α-Synuclein oligomers or Lewy bodies. These data all together could provide novel insights into vitamin D involvement in human astrocyte response during PD. The clinical diagnosis of PD was performed using the UK Brain Bank criteria 19, 20 and confirmed by neuropathological analysis carried out by two experts (GG and MB) in agreement with the current BrainNet Europe Consortium guidelines. 21 Post-mortem human brains obtained from PD patients (n = 9; eight Braak stage 6 of α-Synuclein pathology; one amigdala prevalence) and from control subjects (n = 4) clinically free from neurological diseases were used ( Brains were fixed in 10% buffered formalin for at least 1 month at 20°C. After dehydration and clearing steps, selected areas were paraffin embedded and 5 μm thick frontal cortex, mesencephalic sections, containing substantia nigra, pons, and bulb were cut and processed for the following analysis. Primary and secondary antibodies and kit are summarized in Table 2 . In order to associate Lewy body pathology to CYP27B1 staining, we performed a double immunoenzymatic procedure using anti α-Synuclein (1:500, LB509). The samples were also pretreated with 20% acetic acid for 20 min to inactivate endogenous alkaline phosphatase. The secondary antibodies used were goat anti-mouse conjugated with HRP and rabbit conjugated with alkaline phosphatase. To detect CYP27B1, we used tyramide signal amplification system. The or Tyrosine Hydroxylase 1:200; or LAMP1 1:100 overnight at RT) followed by highly pre-adsorbed secondary antibodies (2 h). A control was performed using CYP27B1 diluted 1:1500 revealed with Alexa Fluor 488 donkey anti-rabbit and gave no signal. Proximity ligation assay was used for α-Synuclein oligomers using red amplification reagent, as previously described. 22 In order to visualize total α-Synuclein, counterstaining. Samples were mounted using Mowiol-DABCO and examined with Nikon spinning disk confocal microscope, equipped with CSI-W1 confocal scanner unit. All quantifications were independently performed using ImageJ (cell counter) by two different operators (FG, SM, or CR). Statistical comparisons were conducted by Mann-Whitney and one-way ANOVA tests. Statistical significance was assessed using GraphPad Prism software. Significance was established at p < 0.05. The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request. We tested whether vitamin D signaling components are altered in PD. In substantia nigra, VDR localized in the nucleus and cytoplasm of neuromelanin containing neurons with no differences between controls and PD patients ( Figure S1 A-C). Besides, vitamin D degrading enzyme CYP24A1 was not altered in PD and was mainly ex- We tested whether CYP27B1 positive astrocyte accumulation is beneficial or detrimental for PD neuropathology. During PD, astrocytes can acquire a neurotoxic phenotype that exacerbate neuronal damage. 6 To determine whether CYP27B1 positive astrocytes have a neurotoxic signature, we analyzed the expression of complement component 3 (C3). 6 We found that among all C3 positive cells in PD substantia nigra, only 4% were CYP27B1, thus indicating that they did not acquire a neurotoxic state (Figure 4 A,B) . Next, we investigated the contribution of CYP27B1 positive as- We therefore hypothesized that CYP27B1 positive astrocytes can be directly linked to α-Synuclein uptake and clearance. We performed proximity ligation assay to detect α-Synuclein oligomers in vivo and found that 74.4% of CYP27B1 positive astrocytes were able to uptake the toxic α-Synuclein aggregates ( Figure 6 A-C and S4 A-B‴). Then, we used LAMP1, a marker for degradative autophagy-lysosomal organelles, 28 in order to discover whether autophagy could be the mechanism involved in α-Synuclein clearance in CYP27B1 positive astrocytes. Notably, we found that α-Synuclein oligomers that are detected inside CYP27B1 positive astrocytes colocalize with LAMP1-positive vesicles ( Figure 6 D and S4 C-D‴), thus suggesting the involvement of an autophagy pathway. Finally, we examined whether the increase in CYP27B1 positive astrocytes correlated with clinical aspects of PD patients (Table 1) . We observed that CYP27B1 expression in the frontal cortex white matter was significantly increased in patients with Lewy body pathology, but without white matter alteration or dementia (Figure 7 A,B,D) . Conversely, PD patients with white matter alterations and concomitant dementia had significantly fewer CYP27B1 positive astrocytes in the cortex (Figure 7 C,D) , despite the total GFAP positive cells were unchanged (Figure 3 C) . Reactive astrocytes heavily contribute to neurodegeneration, and recent evidence suggests that neurotoxic astrocytes accumulate also in the substantia nigra of PD patients. 6 The exact mechanism that drives astrocytes into detrimental alterations (eg, the secretion of neurotoxins) is unknown. Vitamin D prevents these astrocytes alterations in PD mouse model, 29 while vitamin D signaling is unknown in PD patients. We found that activation of vitamin D pathway might be a novel mechanism to prevent the neurotoxic switch of astrocytes. Indeed, CYP27B1 positive astrocytes did not upregulate C3, thus protecting neurons from the complement component-driven synapse degeneration. Synuclein oligomer clearance in vitro in primary cultures and patientderived iPSC model. 2, 5, 30 Starting from these previous papers on cellular model, showing that α-Synuclein fibrils co-localized with LAMP1, a marker for degradative autophagy-lysosomal organelles, 28 we looked for the involvement of the autophagy pathway in α-Synuclein clearance occurring in our samples. The strategy of staining with LAMP1 allowed us to highlight the involvement of autophagy in α-Synuclein clearance that occurs in the complexity and uniqueness of the human brain. Hence, we show for the first time that an astrocyte subpopulation that is positive for CYP27B1 can internalize α-Synuclein oligomers through autophagy in PD patients. Interestingly, these cells morphologically resemble varicose projection astrocytes that are known to be fast conduit in neuron-vascular unit and are characterized by high speed calcium waves. 25 In addition, the overexpression of wild-type or familial mutant α-Synuclein triggers calcium homeostasis alterations. 31 Given the key role of vitamin D in calcium buffering, 32 we speculate that the increase of Vitamin D deficiency may lead to cognitive impairments. [14] [15] [16] [17] Vitamin D supplementation can be beneficial in slowing down PD progression, but the underlying mechanisms are still unknown. 13 13 Further studies are warranted to clarify the complex relationship between vitamin D activation in astrocytes and PD. The authors thank all patients and families for their contribution, and "Fondazione Grigioni per il Morbo di Parkinson" (Milan-Italy) for SM and FG salary and for long-lasting support to GC. Part of this work was carried out at Unitech-NOLIMITS, an advanced imaging facility established by the Università degli Studi di Milano. The authors reported no conflict of interest. The study procedures were in accordance with the principles outlined α-Synuclein transfer between neurons and astrocytes indicates that astrocytes play a role in degradation rather than in spreading Neuron-Astrocyte Interactions in Parkinson's ADP-ribose) drives pathologic αsynuclein neurodegeneration in Parkinson's disease. Science (80-) The Synucleinopathies: Twenty Years On Extensive uptake of α-synuclein oligomers in astrocytes results in sustained intracellular deposits and mitochondrial damage Neurotoxic reactive astrocytes are induced by activated microglia Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease Vitamin D in Neurological Diseases: A Rationale for a Pathogenic Impact Understanding Vitamin D From Mouse Knockout Models Distribution of the Vitamin D receptor and 1α-hydroxylase in human brain Vitamin D and the brain: Genomic and non-genomic actions Association Between Serum Vitamin D Levels and Parkinson's Disease: A Systematic Review and Meta-Analysis Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease Vitamin D, cognition, and dementia: A systematic review and meta-analysis Vitamin D and Risk of Cognitive Decline in Elderly Persons The relationship between balance control and vitamin D in Parkinson's disease-a pilot study Muscle-targeted nutritional support for rehabilitation in patients with parkinsonian syndrome COVID-19 in Parkinson's Disease Patients Living in Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease Staging/typing of Lewy body related α-synuclein pathology: a study of the BrainNet Europe Consortium α-Synuclein oligomers in skin biopsy of idiopathic and monozygotic twin patients with Parkinson's disease Differential expression of vitamin D-associated enzymes and receptors in brain cell subtypes Physiology of Astroglia Phenotypic heterogeneity and plasticity of isocortical and hippocampal astrocytes in the human brain Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinson's Disease and Atypical Parkinsonisms Revisiting LAMP1 as a marker for degradative autophagy-lysosomal organelles in the nervous system Vitamin D Treatment Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in an Animal Model of Parkinson's Disease, Shifting M1 to M2 Microglia Responses Patient-Specific iPSC-Derived Astrocytes Contribute to Non-Cell-Autonomous Neurodegeneration in Parkinson's Disease α-Synuclein binds to the ER-mitochondria tethering protein VAPB to disrupt Ca2+ homeostasis and mitochondrial ATP production New clues about vitamin D functions in the nervous system Potential Role of Vitamin D in the Elderly to Resist COVID-19 and to Slow Progression of Parkinson's Disease